A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to MCV4, Tdap and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 10 Through 12 Years of Age

Phase 2

Completed

Conditions: Vaccines
Meningococcal Vaccines

Registration Number: NCT01461980

Lead Sponsor: Pfizer

Brief Summary: This is a clinical study to assess the safety, tolerance and immunogenic response to MCV4(quadrivalent meningococcal polysaccharide conjugate, meningococcal serogroups A,C,Y, and W135), Tdap (diphtheria, tetanus, and acellular pertussis), and bivalent rLP2086 vaccine. Healthy male and female subjects, between the ages of 10 to 12 years old, will be randomized into 1 of 3 groups. The subjects, investigators, site staff and sponsor will be blinded to all injections given throughout the study. An unblinded administrator will be responsible to administer the vaccinations to all subjects and will be unblinded to the subject randomization in order to determine which subjects were in randomized to group 3 so they may receive their catch-up vaccinations of MCV4 and Tdap. A final telephone contact will be conducted with all subjects 6-months post their last vaccination to obtain safety information.

Detailed Description: Not available

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 2648

Inclusion Criteria

Evidence of a personally signed and dated informed consent document (ICD) indicating that the subject (and a legally authorized representative) has been informed of all pertinent aspects of the study.
Parent /legally authorized representative and subjects who are willing and able to comply with scheduled visits, laboratory tests, and other study procedures.
Male or female subject aged greater than or equal to 10 and <13 years at the time of enrollment.
Available for the entire study period and can be reached by telephone.
Healthy subject as determined by medical history, physical examination, and judgment of the investigator.
Has received full series (5-dose series is preferred, 4-dose catch up series is allowed) of diphtheria, tetanus and pertussis (whole cell or acellular) vaccines per country specific recommendations applicable at the time of receipt.
Male and female subjects of childbearing potential must agree to use a highly effective method of contraception throughout the study.

Exclusion Criteria

Previous vaccination with any meningococcal serogroup B vaccine.
Vaccination with any diphtheria, tetanus or pertussis vaccine within 5 years of the first study vaccination.
Previous vaccination with any MCV4 vaccine.
A previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with MCV4 and/or Tdap vaccine.
Subjects receiving any allergen immunotherapy with a non-licensed product or receiving allergen immunotherapy with a licensed product and are not on stable maintenance doses.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
A known or suspected defect of the immune system that would prevent an immune response to the vaccine, such as subjects with congenital or acquired defects in B cell function, those receiving chronic systemic (oral, intravenous or intramuscular) corticosteroid therapy, or those receiving immunosuppressive therapy. Subjects with terminal complement deficiency may not be included.
History of culture-proven disease caused by Neisseria meningitidis or Neisseria gonorrhoea.
Significant neurological disorder or history of seizure (excluding simple febrile seizure).
Receipt of any blood products, including immunoglobulin within 6 months before the first study vaccination.
Current chronic use of systemic antibiotics.
Any neuroinflammatory or autoimmune condition, including, but not limited to, transverse myelitis, uveitis, optic neuritis, and multiple sclerosis.

Study & Design

Study Type: INTERVENTIONAL

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Geometric Mean Concentrations (GMC) for Diphtheria and Tetanus Antigens	1 Month after Vaccination 1	Antibody GMCs of 2 antigens of diphtheria and tetanus toxoid were computed in International Units per milliliter (IU/mL) along with corresponding 2-sided 95 percent (%) confidence intervals (CIs). Here, 'number of participants analyzed' signifies participants with valid and determinate assay results for given antigen.
Serum Bactericidal Assay Using Human Complement (hSBA) GMTs of PMB80 [A22] and PMB2948 [B24] 1 Month After Vaccination 3	1 Month after Vaccination 3	Antibody hSBA GMTs of primary strain PMB80 \[A22\] and PMB2948 \[B24\] were computed along with corresponding 2-sided 95% CIs. hSBA titers from the 2 primary strains were logarithmically transformed for analysis. Here, 'number of participants analyzed' signifies evaluable immunogenicity population and 'N' signifies participants with valid and determinate assay results for given strain for each group, respectively.
Geometric Mean Concentrations (GMC) for Acellular Pertussis Antigens	1 Month after Vaccination 1	Antibody GMCs of 4 acellular pertussis antigens (pertussis toxoid, pertussis filamentous hemagglutinin, pertussis pertactin and pertussis fimbrial agglutinogens types 2+3) were computed in Enzyme-linked immunosorbent assay (ELISA) units per milliliter (EU/mL) along with corresponding 2-sided 95% CIs.
Geometric Mean Titer (GMT) for Meningococcal Conjugate Vaccine (MCV4) Antigens	1 Month after Vaccination 1	Antibody GMTs of 4 MCV4 antigens (serogroup A, serogroup C, serogroup Y and serogroup W-135) were computed along with corresponding 2-sided 95% CIs.

Secondary Outcome Measures

Name	Time	Method
Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Vaccination 1, 1 Month after Vaccination (Vac) 2, 3	Antibody hSBA of primary strain PMB80 \[A22\] and PMB2948 \[B24\] with hSBA titers \>=1:4, \>=1:8, \>=1:16, \>=1:32, \>=1:64, and \>=1:128 were computed along with corresponding 2-sided 95% CIs.
Percentage of Participants With Seroresponse for Tetanus, Diphtheria and Acellular Pertussis (Tdap) and Meningococcal Conjugate Vaccine (MCV4) Antigens	1 Month after Vaccination 1	Seroconversion rate for Tdap antigens was defined as greater than or equal to (\>=) 4-, 2-fold rise in antibody concentration, if prevaccination antibody concentration was less than or equal to (\<=), greater than (\>) cutoff value, respectively. For MCV4 antigens \>=4-fold rise on serum bactericidal assay using rabbit complement (rSBA) titers if baseline value \>= lower limit of quantitation (LLOQ), postdose rSBA titers \>=2×LLOQ if baseline value was less than (\<) LLOQ. Cutoff value =0.1 IU/mL for diphtheria and tetanus, 0.9,2.9,3.0,10.6 EU/mL for pertussis toxoid, filamentous hemagglutinin, pertactin, fimbriae agglutinogens types 2 + 3, respectively.
Serum Bactericidal Assay Using Human Complement (hSBA) GMTs of PMB80 [A22] and PMB2948 [B24] Before Vaccination 1 and 1 Month After Vaccination 2	Before Vaccination 1, 1 Month after Vaccination (Vac) 2	Antibody hSBA of primary strain PMB80 \[A22\] and PMB2948 \[B24\] were computed along with corresponding 2-sided 95% CIs. hSBA titers from the 2 primary strains were logarithmically transformed for analysis.
Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Lower Limit of Quantitation (LLOQ)	Before Vaccination 1, 1 Month after Vaccination (Vac) 2, 3	Percentage of participants achieving hSBA titer \>= LLOQ were computed along with corresponding 2-sided 95% CIs. LLOQ was 1:16 for PMB80 \[A22\] and 1:8 for PMB2948 \[B24\].
Percentage of Participants Achieving Predefined Antibody Level for Diphtheria and Tetanus Antigens	1 Month after Vaccination 1	Participants with antibody concentration level of greater than or equal to 1.0 IU/mL for diphtheria and tetanus antigens were computed along with corresponding 2-sided 95% CIs.

Trial Locations

Locations (98): Radiant Research, Inc.
🇺🇸
Murray, Utah, United States
Costal Clinical Research, Inc.
🇺🇸
Daphne, Alabama, United States
Clinical Research Advantage Inc/ East Valley Family Physicians, PLC
🇺🇸
Chandler, Arizona, United States
Clinical Research Advantage, Inc./Mesa Family Medical Center, PC
🇺🇸
Mesa, Arizona, United States
Clinical Research Advantage, Inc./Desert
🇺🇸
Mesa, Arizona, United States
The Children's Clinic of Jonesboro, PA
🇺🇸
Jonesboro, Arkansas, United States
Arkansas Pediatric Clinic
🇺🇸
Little Rock, Arkansas, United States
Kaiser Permanente Fresno
🇺🇸
Fresno, California, United States
Kaiser Permanente Hayward
🇺🇸
Hayward, California, United States
Pediatric Care Medical Group
🇺🇸
Huntington Beach, California, United States
Scroll for more (88 remaining)
Radiant Research, Inc.
🇺🇸Murray, Utah, United States